2696 — Shanghai Henlius Biotech Income Statement
0.000.00%
Last trade - 00:00- HK$34.67bn
- HK$37.72bn
- CNY5.72bn
- 70
- 12
- 81
- 57
Annual income statement for Shanghai Henlius Biotech, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 588 | 1,682 | 3,215 | 5,395 | 5,724 |
| Cost of Revenue | |||||
| Gross Profit | 405 | 1,160 | 2,370 | 3,919 | 4,185 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 1,537 | 2,554 | 3,803 | 4,715 | 4,756 |
| Operating Profit | -950 | -872 | -588 | 680 | 969 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -994 | -957 | -694 | 570 | 846 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -994 | -984 | -695 | 546 | 820 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -994 | -984 | -695 | 546 | 820 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -994 | -984 | -695 | 546 | 820 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.87 | -1.79 | -1.28 | 1 | 1.51 |